[To]{.smallcaps} [the Editor---]{.smallcaps}We read with interest the article by Wang et al \[[@CIT0001]\] describing the clinical features of 69 patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Wuhan, China. The authors provide a detailed description of major signs and symptoms of overt disease \[[@CIT0002], [@CIT0003]\], but fail to give an account of minor symptoms that may be present at earlier stages of the infection.

After some patients admitted for coronavirus disease 2019 (COVID-19) at the Infectious Disease Department of L. Sacco Hospital in Milan, Italy, complained of olfactory and taste disorders (OTDs), we performed a cross-sectional survey of the prevalence of these alterations in the context of SARS-CoV-2 infection. On 19 March 2020, a simple questionnaire including questions about the presence or absence of OTDs, their type and time of onset respective to hospitalization were submitted through verbal interview to all SARS-CoV-2--positive hospitalized patients who were able to give informed consent. Of 88 hospitalized patients, 59 were able to be interviewed (29 were nonrespondents, of whom 4 had dementia, 2 had a linguistic barrier, and 23 were on noninvasive ventilation) ([Table 1](#T1){ref-type="table"}). Of these, 20 (33.9%) reported at least 1 taste or olfactory disorder and 11 (18.6%) both. Twelve patients (20.3%) presented the symptoms before the hospital admission, whereas 8 (13.5%) experienced the symptoms during the hospital stay. Taste alterations were more frequently (91%) before hospitalization, whereas after hospitalization taste and olfactory alteration appeared with equal frequency. Females reported OTDs more frequently than males (10/19 \[52.6%\] vs 10/40 \[25%\]; *P =*.036). Moreover, patients with at least 1 OTD were younger than those without (median, 56 years \[interquartile range {IQR}, 47--60\] vs 66 \[IQR, 52--77\]; *P =*.035). All patients reported the persistence of OTDs at the time of the interview.

###### 

Characteristics of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Assessed for Taste and Olfactory Disorders (N = 59)

  Patients                                                      No. (%)
  ------------------------------------------------------------- -------------
  Age, y, median (IQR)                                          60 (50--74)
  Male sex                                                      40 (67.8)
  Days from illness onset to hospital admission, median (IQR)   6 (4--10)
  Days from illness onset to the interview, median (IQR)        15 (10--21)
  Pneumonia at hospital admission                               43 (72.8)
  Symptoms at hospital admission                                
   Fever                                                        43 (72.8)
   Cough                                                        22 (37.3)
   Dyspnea                                                      15 (25.4)
   Sore throat                                                  1 (1.7)
   Arthralgia                                                   3 (5.1)
   Coryza                                                       1 (1.7)
   Headache                                                     2 (3.4)
   Asthenia                                                     1 (1.7)
   Abdominal symptoms                                           5 (8.5)
  No taste or olfactory disorders                               39 (66.1)
  With olfactory and/or taste disorders                         20 (33.9)
  Taste disorders only                                          
   Dysgeusia                                                    5 (8.5)
   Ageusia                                                      1 (1.7)
  Olfactory disorders only                                      
   Hyposmia                                                     3 (5.1)
   Anosmia                                                      0 (0)
  Mixed taste and olfactory disorders                           
   Dysgeusia and hyposmia                                       2 (3.4)
   Dysgeusia and anosmia                                        2 (3.4)
   Ageusia and hyposmia                                         2 (3.4)
   Ageusia and anosmia                                          5 (8.5)

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Olfactory and taste disorders are well known to be related with a wide range of viral infections \[[@CIT0004], [@CIT0005]\]. SARS-CoV has demonstrated in a mice model a transneural penetration through the olfactory bulb \[[@CIT0006]\]. Moreover, angiotensin-converting enzyme 2 receptor, which is used by SARS-CoV-2 to bind and penetrate into the cell, is widely expressed on the epithelial cells of the mucosa of the oral cavity \[[@CIT0007]\]. These findings could explain the underlying pathogenetic mechanism of taste and olfactory disorders in SARS-CoV-2 infection.

Due to limitations related to the diffusivity of the disease and emergency contingencies, it was impossible to perform a more structured questionnaire associated with validated tests (ie, Pennsylvania smell identification test) \[[@CIT0008]\]. However, our survey shows that OTDs are fairly frequent in patients with SARS-CoV-2 infection and may precede the onset of full-blown clinical disease. In a pandemic context, further investigations on nonhospitalized infected patients are required to ascertain if these symptoms, albeit unspecific, may represent a clinical screening tool to orientate testing of pauci-symptomatic individuals.
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